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Adult patients with previously untreated de novo APL were consecutively registered into the JALSG APL97 study. The detail of treatment protocol was described previously. 4 In brief, remission induction was composed by ATRA and chemotherapy including idarubicin and cytarabine. The dose and duration of chemotherapy were based on initial leukocyte count. After completion of consolidation chemotherapy, patients negative for the PML-RARA transcript were randomly allocated either to receive 6 courses of intensified maintenance chemotherapy or to observation. Patients, who were positive for the PML-RARA fusion transcript, received late ATRA therapy followed by maintenance therapy, and received allogeneic hematopoietic stem cell transplantation if they had a human leukocyte antigen-identical donor.
Hematologic response was evaluated by standard criteria according to the previous report. 2 Hematologic and molecular relapse detected by RT-PCR analysis of PML-RARA was considered as a relapse event.
The primary end point of JALSG APL97 study was overall survival (OS) and disease free survival (DFS) of patients who achieved CR. OS for all patients was calculated from the first day of therapy to death or last visit. DFS for patients was measured from the date of CR to relapse, death from any cause or last visit. We also evaluated OS and DFS from the time of randomization to maintenance chemotherapy or observation. had ACAs in chromosome 15 in addition to t(15;17), 6 (9%) in chromosome 9, 6 (9%) in chromosome 7, 4 (6%) in chromosome 15, and 4 (6%) in chromosome 6. Clinical and biological characteristics were not significantly different between two groups, except the frequency of M3v (1% vs. 9%, P = 0.04) ( Table 1 ).
The CR rates in patients with or without ACAs were 97% and 95%, respectively (P = 0.72). The cumulative incidence of early death at 50 days, severe hemorrhagic complication and RA syndrome did not differ between two groups (P = 0.16, P = 0.46 and P = 0.16, respectively).
OS, DFS and cumulative incidence of relapse were neither different between two groups (91% vs. 84%, P = 0.18; 68% vs. 71%, P = 0.59; 26% vs.
22%, P = 0.51, respectively). OS and DFS were shown in Figure 1A and B.
Additionally, the clinical outcome was analyzed among subgroups of patients with ACAs. However, ACAs including chromosome 8, 7, 9, 15 and 17 neither influenced outcomes.
Clinical and biological characteristics have been compared between patients with or without ACAs. ACAs have been detected in 26% to 33% of newly diagnosed APL patients, of which trisomy 8 was consistently the most frequent ACA. [5] [6] [7] [8] [9] In this study, 67 patients (30%) had ACAs, and trisomy 8 was the most frequent (31%). OS, DFS and relapse rate were not significantly different between patients with or without trisomy 8. Figure 1A . Figure 1B . 
